This website requires Javascript for some parts to function propertly. Your experience may vary.

Hengeler Mueller advises Viessmann Generations Group on investment in Pharos | Hengeler Mueller News

Hengeler Mueller advises Viessmann Generations Group on investment in Pharos

The Viessmann Generations Group (“Viessmann”) has acquired a significant minority stake in European pharmaceutical developer and manufacturer PharOS as part of a shareholder consortium with the investment holding Armira. Headquartered on the outskirts of Athens, Greece, PharOS is a pharmaceutical company that develops, manufactures and supplies generics, over-the-counter and value-added products. The company focuses on hard-to-make generic drugs for key treatment areas such as oncology, central nervous or cardiometabolic diseases. With European production capacities and a resilient supply chain, PharOS is a strategic partner for leading pharmaceutical companies.

Hengeler Mueller team for Viessmann Generation Group 

M&A/Corporate: Matthias Hentzen (lead, partner, Düsseldorf), Jan Häller (Frankfurt), Matthias Marz (both senior associates, Düsseldorf),

Public law: Michael Schramm (partner), Jan Schülting (senior associate, both Düsseldorf),

Antitrust: Thorsten Mäger (partner), Anja Balitzki (counsel), Leonie Lentner (associate, all Düsseldorf).

Latest Articles

Hengeler Mueller advises BAWAG on successful closing of the acquisition of the German retail business from Barclays

Hengeler Mueller advises METRO on Delisting

Hengeler Mueller advises Paragon Partners on acquisition of DYMATRIX

Recent Mergers & Acquisitions Work